Dual treatment combining HER2-targeted therapy (Lapatinib) with the CDK7 inhibitor THZ1 strongly inhibits HER2+ breast cancer cell growth and increases apoptosis in cancer cells that exhibit resistance to HER2-targeted therapies.357. This evidence concerns the gene CDK7 and cancer.